Triple negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, comprises 10–20% of all breast cancers [1]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.